ALK and non-small cell lung carcinoma: In this nonrandomized controlled trial, we found that the combination of atezolizumab plus bevacizumab as first-line treatment for patients with advanced nonsquamous NSCLC with high TMB and no EGFR or ALK genomic alterations was associated with encouraging survival rates and durable responses, with a favorable safety profile.